Ethyl ferulate, a lipophilic phenylpropanoid, prevents diabetes-associated renal injury in rats by amelioration of hyperglycemia-induced oxidative stress via activation of nuclear factor erythroid 2-related factor 2.
Nrf2 activation
adjuvant therapy
diabetic nephropathy
ethyl ferulate
oxidative stress
Journal
Journal of food biochemistry
ISSN: 1745-4514
Titre abrégé: J Food Biochem
Pays: United States
ID NLM: 7706045
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
10
12
2020
received:
22
02
2020
accepted:
14
12
2020
pubmed:
16
2
2021
medline:
9
7
2021
entrez:
15
2
2021
Statut:
ppublish
Résumé
Diabetic nephropathy affects approximately 20%-40% of diabetes patients worldwide and is the leading cause of end-stage renal failure. Oxidative stress has been identified as a major causative factor in the development and progression of diabetic nephropathy; Nuclear factor erythroid 2-related factor 2 (Nrf2) activation protects the body against oxidative stress by induction of antioxidant enzymes. The renoprotective effect of ethyl ferulate was investigated in diabetes-induced renal injury. Ethyl ferulate was administered orally at three doses (50 mg/kg, 75 mg/kg, and 100 mg/kg). Metformin (500 mg/kg, p.o.) was used as a standard. Ethyl ferulate treatment decreased serum advanced glycation end products, glycosylated hemoglobin (HbA1c) levels, renal oxidative stress, tumor necrosis factor-α (TNF-α) level, and kidney hypertrophy index. It restored serum lipid profile, biomarkers of renal function, and mitigated histopathological signs of renal damage. Immunohistochemistry demonstrated higher Nrf2 protein levels in kidney sections of ethyl ferulate-treated rats. These findings suggest that ethyl ferulate ameliorated hyperglycemia-induced oxidative stress by increasing renal Nrf2 levels, thereby preventing diabetes-induced kidney injury. In conclusion, the present study endorses the usefulness of Nrf2 activators, such as ethyl ferulate, as adjuvant therapy for preventing the diabetic nephropathy. PRACTICAL APPLICATIONS: Ethyl ferulate (ethyl-3-hydroxyl-4-methoxycinnamate), a phenylpropanoid, is a naturally occurring ethyl ester of ferulic acid and is widely present in plants and especially grains, such as rice and maize. Our study has highlighted the renoprotective effect of ethyl ferulate in preventing diabetes-associated renal injury. The observed effect of ethyl ferulate is due to amelioration of diabetes-induced oxidative stress and inflammation, by activation of the Nrf2 pathway. These results indicate the potential of ethyl ferulate as a nutraceutical or adjuvant therapy in prevention of diabetic nephropathy.
Substances chimiques
Caffeic Acids
0
NF-E2-Related Factor 2
0
ethyl ferulate
5B8915UELW
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13607Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Antonio, C., Michael, A. I., & Jessica, E. T. (2009). The “metabolic memory”: Is more than just tight glucose control necessary to prevent diabetic complications? The Journal of Clinical Endocrinology & Metabolism, 94(2), 410-415. https://doi.org/10.1210/jc.2008-1824
Ayala, A., Munoz, M. F., & Arguelles, S. (2014). Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Medicine and Cellular Longevity, 2014, 360438. https://doi.org/10.1155/2014/360438
Ayodele, O. E., Alebiosu, C. O., & Salako, B. L. (2004). Diabetic nephropathy-A review of the natural history, burden, risk factors and treatment. Journal of the National Medical Association, 96(11), 1445-1454.
Boden, G., & Laakso, M. (2004). Lipids and glucose in type 2 diabetes: What is the cause and effect? Diabetes Care, 27(9), 2253-2259. https://doi.org/10.2337/diacare.27.9.2253
Brownlee, M. (2005). The pathobiology of diabetic complications. A unifying mechanism. Diabetes, 54(6), 1615-1625.
Cunha, F. V. M., Coelho, A. G., Azevedo, P., da Silva, A. A. J., Oliveira, F. A., & Nunes, L. C. C. (2019). Systematic review and technological prospection: Ethyl ferulate, a phenylpropanoid with antioxidant and neuroprotective actions. Expert Opinion on Therapeutic Patents, 29(2), 73-83. https://doi.org/10.1080/13543776.2019.1568410
Cunha, F. V., Gomes, B., Neto, B., Ferreira, A. R., de Sousa, D. P., de Carvalho e Martins, M., & Oliveira, F. (2016). Ferulic acid ethyl ester diminished Complete Freund's Adjuvant-induced incapacitation through antioxidant and anti-inflammatory activity. Naunyn-Schmiedeberg's Archives of Pharmacology, 389(1), 117-130. https://doi.org/10.1007/s00210-015-1180-8
Dabla, P. K. (2010). Renal function in diabetic nephropathy. World Journal of Diabetes, 1(2), 48-56. https://doi.org/10.4239/wjd.v1.i2.48
David, J. A., Rifkin, W. J., Rabbani, P. S., & Ceradini, D. J. (2017). The Nrf2/Keap1/ARE pathway and oxidative stress as a therapeutic target in type II diabetes mellitus. Journal of Diabetes Research, 2017, 4826724. https://doi.org/10.1155/2017/4826724
Donate-Correa, J., Martin-Nunez, E., Muros-de-Fuentes, M., Mora-Fernandez, C., & Navarro-Gonzalez, J. F. (2015). Inflammatory cytokines in diabetic nephropathy. Journal of Diabetes Research, 2015, 948417. https://doi.org/10.1155/2015/948417
Dumitrescu, R., Mehedintu, C., Briceag, I., Purcarea, V. L., & Hudita, D. (2015). Metformin-clinical pharmacology in PCOs. Journal of Medicine and Life, 8(2), 187-192.
Fakhruddin, S., Alanazi, W., & Jackson, K. E. (2017). Diabetes-induced reactive oxygen species: Mechanism of their generation and role in renal injury. Journal of Diabetes Research, 2017, 8379327. https://doi.org/10.1155/2017/8379327
Fukami, K., Yamagishi, S., Ueda, S., & Okuda, S. (2008). Role of AGEs in diabetic nephropathy. Current Pharmaceutical Design, 14(10), 946-952. https://doi.org/10.2174/138161208784139710
Gawel, S., Wardas, M., Niedworok, E., & Wardas, P. (2004). Malondialdehyde (MDA) as a lipid peroxidation marker. Wiadomosci Lekarskie, 57(9-10), 453-455.
Ghule, A. E., Jadhav, S. S., & Bodhankar, S. L. (2012). Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic (nSTZ) rats. International Immunopharmacology, 14(4), 740-748. https://doi.org/10.1016/j.intimp.2012.10.004
Ghumatkar, P. J., Patil, S. P., Jain, P. D., Tambe, R. M., & Sathaye, S. (2015). Nootropic, neuroprotective and neurotrophic effects of phloretin in scopolamine induced amnesia in mice. Pharmacology, Biochemistry and Behavior, 135, 182-191. https://doi.org/10.1016/j.pbb.2015.06.005
Goldberg, I. J. (2001). Clinical review 124: Diabetic dyslipidemia: Causes and consequences. Journal of Clinical Endocrinology and Metabolism, 86(3), 965-971. https://doi.org/10.1210/jcem.86.3.7304
Gowda, S., Desai, P. B., Kulkarni, S. S., Hull, V. V., Math, A. A., & Vernekar, S. N. (2010). Markers of renal function tests. North American Journal of Medical Sciences, 2(4), 170-173.
Guerin-Dubourg, A., Cournot, M., Planesse, C., Debussche, X., Meilhac, O., Rondeau, P., & Bourdon, E. (2017). Association between fluorescent advanced glycation end-products and vascular complications in type 2 diabetic patients. BioMed Research International, 2017, 7989180. https://doi.org/10.1155/2017/7989180
Howard, B. V. (1987). Lipoprotein metabolism in diabetes mellitus. Journal of Lipid Research, 28(6), 613-628.
Intine, R. V., & Sarras, M. P., Jr. (2012). Metabolic memory and chronic diabetes complications: Potential role for epigenetic mechanisms. Current Diabetes Reports, 12(5), 551-559. https://doi.org/10.1007/s11892-012-0302-7
Kaikini, A. A., Kanchan, D. M., Nerurkar, U. N., & Sathaye, S. (2017). Targeting mitochondrial dysfunction for the treatment of diabetic complications: Pharmacological interventions through natural products. Pharmacognosy Reviews, 11(22), 128-135. https://doi.org/10.4103/phrev.phrev_41_16
Kanchan, D. M., Somani, G. S., Peshattiwar, V. V., Kaikini, A. A., & Sathaye, S. (2016). Renoprotective effect of diosgenin in streptozotocin induced diabetic rats. Pharmacological Reports, 68(2), 370-377. https://doi.org/10.1016/j.pharep.2015.10.011
Kashihara, N., Haruna, Y., Kondeti, V. K., & Kanwar, Y. S. (2010). Oxidative stress in diabetic nephropathy. Current Medicinal Chemistry, 17(34), 4256-4269. https://doi.org/10.2174/092986710793348581
Kato, M., & Natarajan, R. (2019). Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nature Reviews Nephrology, 15(6), 327-345. https://doi.org/10.1038/s41581-019-0135-6
Keating, S. T., van Diepen, J. A., Riksen, N. P., & El-Osta, A. (2018). Epigenetics in diabetic nephropathy, immunity and metabolism. Diabetologia, 61(1), 6-20. https://doi.org/10.1007/s00125-017-4490-1
Kikuzaki, H., Hisamoto, M., Hirose, K., Akiyama, K., & Taniguchi, H. (2002). Antioxidant properties of ferulic acid and its related compounds. Journal of Agricultural and Food Chemistry, 50(7), 2161-2168. https://doi.org/10.1021/jf011348w
Li, R., Jia, Z., & Zhu, H. (2019). Regulation of Nrf2 signaling. Reactive Oxygen Species (Apex), 8(24), 312-322.
Lyons, T. J., & Basu, A. (2012). Biomarkers in diabetes: Hemoglobin A1c, vascular and tissue markers. Translational Research, 159(4), 303-312. https://doi.org/10.1016/j.trsl.2012.01.009
Marshall, C. B. (2016). Rethinking glomerular basement membrane thickening in diabetic nephropathy: Adaptive or pathogenic? American Journal of Physiology. Renal Physiology, 311(5), F831-F843. https://doi.org/10.1152/ajprenal.00313.2016
Maruf, A. A., Lip, H., Wong, H., & O'Brien, P. J. (2015). Protective effects of ferulic acid and related polyphenols against glyoxal- or methylglyoxal-induced cytotoxicity and oxidative stress in isolated rat hepatocytes. Chemico-Biological Interactions, 234, 96-104. https://doi.org/10.1016/j.cbi.2014.11.007
Miner, J. H. (2012). The glomerular basement membrane. Experimental Cell Research, 318(9), 973-978. https://doi.org/10.1016/j.yexcr.2012.02.031
Münch, G., Keis, R., Weßels, A., Riederer, P., Bahner, U., Heidland, A., Niwa, T., Lemke, H.-D., & Schinzel, R. (1997). Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. European Journal of Clinical Chemistry and Clinical Biochemistry, 35(9), 669-677. https://doi.org/10.1515/cclm.1997.35.9.669
Palsamy, P., & Subramanian, S. (2011). Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochimica et Biophysica Acta, 1812(7), 719-731. https://doi.org/10.1016/j.bbadis.2011.03.008
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice, 157, 107843. https://doi.org/10.1016/j.diabres.2019.107843
Scapagnini, G., Vasto, S., Abraham, N. G., Caruso, C., Zella, D., & Fabio, G. (2011). Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Molecular Neurobiology, 44(2), 192-201. https://doi.org/10.1007/s12035-011-8181-5
Singh, V. P., Bali, A., Singh, N., & Jaggi, A. S. (2014). Advanced glycation end products and diabetic complications. The Korean Journal of Physiology & Pharmacology, 18(1), 1-14. https://doi.org/10.4196/kjpp.2014.18.1.1
Suryavanshi, S. V., & Kulkarni, Y. A. (2017). NF-kappabeta: A potential target in the management of vascular complications of diabetes. Frontiers in Pharmacology, 8, 798. https://doi.org/10.3389/fphar.2017.00798
Testa, R., Bonfigli, A. R., Prattichizzo, F., La Sala, L., De Nigris, V., & Ceriello, A. (2017). The “metabolic memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients, 9(5), 437. https://doi.org/10.3390/nu9050437
van Stee, M. F., de Graaf, A. A., & Groen, A. K. (2018). Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular Diabetology, 17(1), 94. https://doi.org/10.1186/s12933-018-0738-4
Verges, B. (2015). Pathophysiology of diabetic dyslipidaemia: Where are we? Diabetologia, 58(5), 886-899. https://doi.org/10.1007/s00125-015-3525-8
Villeneuve, L. M., Reddy, M. A., & Natarajan, R. (2011). Epigenetics: Deciphering its role in diabetes and its chronic complications. Clinical and Experimental Pharmacology & Physiology, 38(7), 451-459. https://doi.org/10.1111/j.1440-1681.2011.05497.x
Vomund, S., Schafer, A., Parnham, M. J., Brune, B., & von Knethen, A. (2017). Nrf2, the master regulator of anti-oxidative responses. International Journal of Molecular Sciences, 18(12), 2772. https://doi.org/10.3390/ijms18122772
Wardyn, J. D., Ponsford, A. H., & Sanderson, C. M. (2015). Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways. Biochemical Society Transactions, 43(4), 621-626. https://doi.org/10.1042/BST20150014
Xue, M., Rabbani, N., Momiji, H., Imbasi, P., Anwar, M. M., Kitteringham, N., Park, B. K., Souma, T., Moriguchi, T., Yamamoto, M., & Thornalley, P. J. (2012). Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. The Biochemical Journal, 443(1), 213-222. https://doi.org/10.1042/BJ20111648